BAM15

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

Small molecule mitochondrial protonophore (uncoupler) that selectively increases energy expenditure by dissipating the mitochondrial proton gradient, reducing body fat and improving insulin sensitivity without hyperthermia.

Note: BAM15 is a small molecule mitochondrial uncoupler, NOT a peptide. It is included in the Ageless Peps catalog alongside peptide products due to its metabolic applications, similar to MK-677, Tesofensine, and Orforglipron. BAM15 is classified as an N-alkyl-5-(2-thienyl)-1,2-oxazol-3-amine derivative.

Quick Facts

Property	Value
Also Known As	BAM-15, N5-(2-methoxybenzyl)-2-(2-methyl-1H-imidazol-1-yl)-N5-(4-methylphenyl)-1,3-oxazole-4,5-diamine
Category	Metabolic / Weight Loss / Mitochondrial Uncoupler
Sequence	N/A (small molecule, not a peptide)
Molecular Weight	~340 Da
Molecular Formula	C22H23N5O2
PubChem CID	56671008
Administration	Oral
Typical Dose Range	Preclinical only — no established human dose (mouse studies: 50-100 mg/kg/day)
Half-Life	Not fully characterized in humans
Storage	Room temperature; protect from moisture and light
FDA Status	Research only — NOT approved for any human indication
WADA Status	Not listed (not yet classified)

Mechanism of Action

BAM15 is a mitochondrial-selective protonophore that uncouples oxidative phosphorylation by increasing proton conductance across the inner mitochondrial membrane. Under normal physiology, the electron transport chain (ETC) pumps protons from the mitochondrial matrix into the intermembrane space, creating an electrochemical gradient (proton motive force) that drives ATP synthase (Complex V) to produce ATP. BAM15 provides an alternative pathway for protons to leak back into the matrix, bypassing ATP synthase. This dissipates the gradient as heat rather than ATP, forcing the cell to increase substrate oxidation (fatty acids, glucose) to maintain the gradient — effectively increasing energy expenditure (PMID: 24634817).

The critical pharmacological advantage of BAM15 over older uncouplers (2,4-dinitrophenol/DNP, FCCP) is its selectivity for the inner mitochondrial membrane. DNP and FCCP depolarize both the mitochondrial and plasma membranes, leading to cytotoxicity and, in the case of DNP, fatal hyperthermia at supratherapeutic doses. BAM15 does not depolarize the plasma membrane at concentrations that maximally uncouple mitochondria, providing a substantially wider therapeutic window (PMID: 24634817). In head-to-head comparisons, BAM15 stimulates an equal or higher maximum rate of mitochondrial respiration compared to FCCP but is significantly less cytotoxic.

In diet-induced obese mice, oral BAM15 increased nutrient oxidation and decreased body fat mass without affecting food intake, lean body mass, body temperature, or causing biochemical or haematological toxicity. Hyperinsulinemic-euglycemic clamp studies demonstrated improved insulin sensitivity in liver, skeletal muscle, and adipose tissue. BAM15 also reduced hepatic steatosis and inflammatory lipid species (ceramides, diacylglycerols), suggesting direct benefits in NAFLD/MASH beyond weight loss alone (PMID: 32409697).

Key Research Areas

Obesity and fat loss — Oral BAM15 reverses diet-induced obesity in mice by increasing caloric expenditure through mitochondrial uncoupling, without reducing food intake or lean mass (PMID: 32409697)
Insulin resistance and type 2 diabetes — Multi-tissue insulin sensitization demonstrated via gold-standard clamp studies; improvements in glycemic control independent of weight loss in some models (PMID: 32519812)
NAFLD/MASH (hepatic steatosis) — Reduces hepatic fat accumulation and inflammatory lipid species; potential therapeutic for metabolic-associated fatty liver disease (PMID: 32409697)
Renal protection — Original discovery showed dose-dependent protection against acute renal ischemia-reperfusion injury (PMID: 24634817)
Anti-inflammation — Attenuates LPS-induced inflammation in macrophages and hepatocytes (PMID: 34062536)
Cancer — Induces ROS production in acute myeloid leukemia cells, promoting apoptosis (PMID: 35192847)

Evidence Level Summary

Evidence Type	Count	Notes
Human RCTs	0	No human clinical trials to date
Human observational	0	No human data
Animal in vivo	5+	DIO mice, renal ischemia, sarcopenic obesity, inflammation models
In vitro	3+	Cell lines, primary hepatocytes, L6 myotubes
Systematic reviews	0	None published
Narrative reviews	1	Comprehensive review (2023) covering all disease models

Clinical Applications

Weight Management — Energy expenditure-driven fat loss without appetite suppression
Fat Loss — Preferential reduction in adipose tissue with preservation of lean mass
Metabolic Syndrome — Multi-tissue insulin sensitization
NAFLD — Hepatic fat reduction and anti-inflammatory lipid modulation

Protocols Using This Peptide

Weight Loss Protocol — Potential adjunct (preclinical stage)
Metabolic Reset Protocol — Potential adjunct (preclinical stage)

Ageless Peps Products

AP-BAM15-Capsules — BAM15 capsules (WC ID 794, DRAFT — not yet published)

Dosing Reference

Research Dosing Ranges (from literature)

Route	Dose Range	Frequency	Duration	Source
Oral (mouse)	50 mg/kg/day	Daily (in diet)	6-8 weeks	PMID 32409697
Oral (mouse)	100 mg/kg/day	Daily (in diet)	Variable	PMID 32519812

Important: No human dosing data exists. All dosing information is from preclinical mouse studies and cannot be directly extrapolated to humans. Allometric scaling is required and has not been validated for BAM15.

Cycling

No cycling protocols established. Preclinical studies used continuous daily dosing.

Contraindications & Safety

Contraindications: No human data; theoretically contraindicated in conditions where mitochondrial uncoupling may be harmful (mitochondrial myopathies, severe cardiac disease)
Common side effects: None characterized in humans; mouse studies showed no toxicity at effective doses
Drug interactions: Theoretical — avoid combination with other mitochondrial-targeted agents; may potentiate hypoglycemic drugs
Pregnancy/nursing: Unknown; not recommended (no reproductive toxicity data)
Special populations: No data on renal, hepatic impairment, pediatric, or geriatric populations

Synergistic Combinations

5-Amino-1MQ + BAM15 — Complementary metabolic mechanisms: NNMT inhibition (NAD+ restoration) + mitochondrial uncoupling (energy expenditure). Both target different aspects of metabolic dysfunction
SLU-PP-332 + BAM15 — ERR pan-agonist (exercise mimetic) + uncoupler. AP sells a SLU-PP-332/BAM15 blend (WC ID 797, draft)
MOTS-C + BAM15 — Mitochondrial-derived peptide (AMPK activation) + uncoupler. Complementary mitochondrial approaches
AOD-9604 + BAM15 — Lipolytic GH fragment + uncoupler for multi-mechanism fat loss

Related Research

PMID	Title	Year	Study Type
24634817	Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane	2014	In vitro / Animal
32409697	BAM15 reverses diet-induced obesity and insulin resistance in mice	2020	Animal in vivo
37900126	BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases	2023	Narrative Review

References

PMID 24634817 — Discovery and characterization of BAM15
PMID 32409697 — Landmark obesity/insulin resistance study (Nature Communications)
PMID 32519812 — Obesity protection and glycemic control
PMID 37900126 — Comprehensive review of BAM15 therapeutic applications
PMID 34062536 — Anti-inflammatory effects
PMID 35192847 — Cancer (AML) applications
PMID 35304976 — Sarcopenic obesity and muscle quality

#metabolic #oral #small-molecule #not-a-peptide #mitochondrial